Sharp, a provider of contract packaging and clinical trial supply chain solutions services, has completed the first phase of $23m investment in a clinical services facility in the US state of Pennsylvania.
The company acquired the facility located in Bethlehem for $14m last year.
The $2.5m relocation project transfer the company’s clinical storage and distribution services from its Phoenixville site.
Phase two will see the company co-locate its clinical services offering at the site when its packaging, manufacturing and analytical services are shifted to it in late-2018.
According to Sharp, the development project at the Bethlehem facility presents 1.5 million cubic feet of capacity on a 16-acre plot. Further, it will enable the company to expand pallet space for cold and controlled-temperature storage alike by nearly 50%.
Sharp Clinical Services president Frank Lis said: “The Bethlehem facility is a strategically important investment for Sharp. It will allow us to offer greater capacity, scalability and automation in response to growing demand for our services, as well as co-locating our clinical services at one facility.
“This facility allows us to simultaneously support multiple large-scale phase III studies through to commercial launch.”
Sharp said that its investment in the Bethlehem has made room for new clinical services capacity which is in line with its capacity expansion to support existing clients and address future demand.
The company is a division of UDG healthcare and has facilities in the US and Europe.
Image: Sharp invested $23m for the first phase development of its Bethlehem site. Photo: courtesy of Sharp.